Anixa Biosciences is trading 6.8% down at $3.00 in a likely pullback following several strong sessions earlier this week.
- No new company-specific news or regulatory filings have emerged so far to explain the downward move.
- The decline appears to be driven by profit-taking, as the broader market maintains a modestly positive tone.
- The stock is retracing after a period of significant gains seen in previous sessions.